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Research
The developmental neurotoxicity of organo-
phosphate pesticides occurs at doses below
the threshold for overt symptoms of intoxica-
tion, or even lower than that required for
cholinesterase inhibition, the standard bio-
marker for exposure and risk assessment
(reviewed by Slotkin 1999, 2004, 2005).
These agents alter the trajectory of neuro-
development and formation of neural circuits
through a family of mechanisms targeting cell
replication and differentiation, axonogenesis
and synaptogenesis, and functional develop-
ment of neurotransmitter and neurotrophin
systems, culminating in adverse effects on
behavioral performance. Although the
organophosphates damage a wide variety of
neurotransmitter networks, those involving
acetylcholine (ACh) nevertheless represent a
major target, in part because some of these
agents speciﬁcally redirect differentiation away
from expression of the cholinergic phenotype
(Jameson et al. 2006; Slotkin et al. 2001,
2007b) and also because developing choliner-
gic neurons and nerve terminals may be espe-
cially vulnerable to toxicant damage (Slotkin
1999, 2004, 2005). Accordingly, tests of cog-
nitive performance, which depend heavily
upon cholinergic function, readily reveal the
adverse effects of developmental exposure to
organophosphates (Chanda and Pope 1996;
Jett et al. 2001; Levin et al. 2001). The same
conclusions have been reached from behavioral
tests of children living in environments with
high organophosphate levels (Guillette et al.
1998; Landrigan 2001; Rauh et al. 2006).
The fact that organophosphate effects on
brain development involve mechanisms other
than their common feature of cholinesterase
inhibition raises the likelihood that different
members of this pesticide class could evoke
dissimilar neurodevelopmental outcomes, so
that some may pose greater neurotoxic risk
than others at the same low-level exposures.
This is a signiﬁcant concern: Whereas there is
a vast literature on the effects of chlorpyrifos,
there is much less information available about
the consequences of fetal or neonatal exposure
to other organophosphates in widespread use,
such as diazinon (DZN). Previous work both
in vitro and in vivo suggests that there are sim-
ilarities, but also substantial differences, in the
initial effects of these two agents as well as in
their ultimate neurobehavioral consequences
(Jameson et al. 2007; Qiao et al. 2001, 2003,
2004; Slotkin et al. 2006a, 2007b, 2007c;
Slotkin and Seidler 2007a; Timofeeva et al.
2008). In the present study, we focused on the
effects of neonatal DZN exposure on indices
of neural cell development and ACh systems
in adolescence and adulthood, modeling our
measures after earlier studies with chlorpyrifos
(Campbell et al. 1997; Dam et al. 1999; Qiao
et al. 2002, 2003, 2004; Rhodes et al. 2004;
Slotkin et al. 2001, 2006a). We administered
DZN during the immediate postnatal period
[postnatal days (PNDs) 1–4], a stage at which
we previously found high sensitivity of ACh
systems to disruption by chlorpyrifos. Because
of our interest in mechanisms other than
cholinesterase inhibition, we evaluated two
apparently nonsymptomatic DZN regimens
(Slotkin et al. 2006a, 2006b; Slotkin and
Seidler 2007a): 0.5 mg/kg/day, which pro-
duces no discernible cholinesterase inhibition,
and 2 mg/kg/day, which elicits approximately
20% inhibition, equivalent to that obtained
with 1 mg/kg/day of chlorpyrifos as used in
our earlier work (Song et al. 1997). Because
many of the developmental effects of chlor-
pyrifos are strongly sex-selective (Aldridge
et al. 2004, 2005a; Dam et al. 2000; Levin
et al. 2001, 2002; Slotkin 2005; Slotkin et al.
2001, 2002; Slotkin and Seidler 2007b), we
evaluated both males and females for compa-
rable effects of DZN.
To characterize the effects on neural cell
development, we conducted measurements of
DNA and cell protein fractions that character-
ize cell-packing density, cell number, and cell
size. The DNA concentration (DNA per unit
tissue weight), reflects the cell-packing den-
sity, whereas the DNA content (DNA per
brain region) indicates the total number of
cells (Bell et al. 1987; Slotkin et al. 1984;
Winick and Noble 1965). The ratio of total
protein/DNA rises as the size of the cell
increases (Bell et al. 1987; Slotkin et al. 1984).
The relative cell-membrane surface area, eval-
uated by the ratio of membrane protein/total
protein changes in two ways. Replacement of
neurons with smaller glial cells results in an
increase in the surface/volume ratio and a cor-
responding rise in the membrane/total protein
ratio. However, the development of neuritic
projections also necessitates an increase in the
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BACKGROUND: The developmental neurotoxicity of organophosphate pesticides involves mechanisms
other than their shared property of cholinesterase inhibition. 
OBJECTIVES: We gave diazinon (DZN) to newborn rats on postnatal days 1–4, using doses (0.5 or
2 mg/kg) spanning the threshold for barely detectable cholinesterase inhibition. 
METHODS: We then evaluated the lasting effects on indices of neural cell number and size, and on
functional markers of acetylcholine (ACh) synapses (choline acetyltransferase, presynaptic high-
afﬁnity choline transporter, nicotinic cholinergic receptors) in a variety of brain regions. 
RESULTS: DZN exposure produced a signiﬁcant overall increase in cell-packing density in adolescence
and adulthood, suggestive of neuronal loss and reactive gliosis; however, some regions (temporal/
occipital cortex, striatum) showed evidence of net cell loss, reﬂecting a greater sensitivity to neuro-
toxic effects of DZN. Deﬁcits were seen in ACh markers in cerebrocortical areas and the hippocam-
pus, regions enriched in ACh projections. In contrast, there were no significant effects in the
midbrain, the major locus for ACh cell bodies. The striatum showed a unique pattern, with robust
initial elevations in the ACh markers that regressed in adulthood to normal or subnormal values. 
CONCLUSIONS: These results indicate that developmental exposures to apparently nontoxic doses of
DZN compromise neural cell development and alter ACh synaptic function in adolescence and
adulthood. The patterns seen here differ substantially from those seen in earlier work with chlor-
pyrifos, reinforcing the concept that the various organophosphates have fundamentally different
effects on the developmental trajectories of specific neurotransmitter systems, unrelated to their
shared action as cholinesterase inhibitors.
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[Online 13 December 2007]contribution of membrane proteins relative to
other cell proteins (Campbell et al. 1997;
Qiao et al. 2002, 2003; Slotkin et al. 2007a,
2007b; Song et al. 1998).
For effects on ACh synaptic function, we
assessed three markers: activity of choline
acetyltransferase (ChAT), cell membrane
binding of hemicholinium-3 (HC3) to the
presynaptic high-afﬁnity choline transporter,
and the concentration of α4β2 nicotinic
acetylcholine receptors (nAChRs). ChAT, the
enzyme that synthesizes acetylcholine, is a
constitutive component of cholinergic nerve
terminals and thus provides a measure of the
development of cholinergic projections (Dam
et al. 1999; Happe and Murrin 1992;
Monnet-Tschudi et al. 2000; Qiao et al. 2003;
Richardson and Chambers 2005; Slotkin et al.
2001). In contrast, HC3 binding to the
choline transporter is responsive to neuronal
activity (Klemm and Kuhar 1979; Simon et al.
1976), so that measurement of both parame-
ters enables the distinction between effects on
the development of innervation from those on
synaptic activity. These markers have been
used previously to characterize effects of chlor-
pyrifos on ACh systems in adult rats (Liu and
Pope 1996, 1998) and to evaluate the imme-
diate and delayed effects of postnatal chlor-
pyrifos exposure (Dam et al. 1999; Rhodes
et al. 2004; Richardson and Chambers 2005;
Slotkin et al. 2001). Finally, the α4β2 nAChR
is the most abundant nAChR subtype in the
mammalian brain (Flores et al. 1992; Happe
et al. 1994; Whiting and Lindstrom 1987,
1988); this receptor plays important roles in
the ability of ACh systems to release other
neurotransmitters involved in critical pathways
such as those regulating reward, cognition,
and mood (Buisson and Bertrand 2001, 2002;
Dani and De Biasi 2001; Fenster et al. 1999;
Quick and Lester 2002).
Methods
Animal treatments. All experiments were car-
ried out humanely and with regard for allevia-
tion of suffering, with protocols approved by
the Institutional Animal Care and Use
Committee and in accordance with all federal
and state guidelines. Timed-pregnant
Sprague-Dawley rats (Charles River, Raleigh,
NC) were housed in breeding cages, with a
12-hr light–dark cycle and free access to food
and water. On the day after birth, all pups
were randomized and redistributed to the
dams with a litter size of 10 (five males, five
females) to maintain a standard nutritional
status. Because of its poor water solubility,
DZN (Chem Service, West Chester, PA) was
dissolved in dimethylsulfoxide to provide con-
sistent absorption (Slotkin et al. 2006a,
2006b; Slotkin and Seidler 2007a; Whitney
et al. 1995) and was injected subcutaneously
in a volume of 1 mL/kg once daily on PNDs
1–4; control animals received equivalent injec-
tions of the dimethylsulfoxide vehicle, which
does not itself produce developmental neuro-
toxicity (Whitney et al. 1995). Doses of 0.5 and
2 mg/kg/day were chosen because they lie
below the threshold for signs of systemic toxic-
ity in developing rats, as evidenced by impaired
viability or reduced weight gain (Slotkin et al.
2006a), and they straddle the threshold for
barely detectable cholinesterase inhibition
(Slotkin and Seidler 2007a; Slotkin et al.
2006b). These treatments thus resemble the
nonsymptomatic exposures reported in preg-
nant women (De Peyster et al. 1993) and are
pharmacodynamically comparable to expected
fetal and childhood exposures after routine
home application or in agricultural communi-
ties (Gurunathan et al. 1998; Ostrea et al.
2002). Randomization of pup litter assign-
ments within treatment groups was repeated at
intervals of several days up until weaning; in
addition, dams were rotated among litters to
distribute any maternal caretaking differences
randomly across litters and treatment groups.
Offspring were weaned on PND21.
On PNDs 30, 60, and 100, one male and
one female were selected from each litter of ori-
gin and were decapitated. The cerebellum
(including ﬂocculi) was removed, and the mid-
brain/brainstem was separated from the fore-
brain by a cut rostral to the thalamus. The
striatum and hippocampus were then dissected
from these larger divisions, and the midbrain
and brainstem were divided from each other.
The cerebral cortex was divided down the mid-
line and then further sectioned into anterior
and posterior regions (frontal/parietal cortex
and temporal/occipital cortex, respectively).
The experiments in the present study were per-
formed on the frontal/parietal cortex and tem-
poral/occipital cortex, the striatum, and the
hippocampus, all of which contain the major
ACh projections, and the midbrain, which
contains the cell bodies projecting to the other
regions. The brainstem was used solely for
determinations of DNA and proteins, whereas
the cerebellum was not evaluated, because it is
sparse in ACh projections or cell bodies.
Tissues were frozen with liquid nitrogen and
stored at –45°C.
Markers of neural cell number and size.
Each tissue was thawed and homogenized
(Polytron, Brinkmann Instruments, Westbury,
NY) in ice-cold 10-mM sodium–potassium
phosphate buffer (pH 7.4), and aliquots of
the homogenate were withdrawn for measure-
ment of DNA and total protein. DNA was
assessed with a fluorescent dye-binding
method (Trauth et al. 2000). Aliquots were
diluted in 50 mM sodium phosphate, 2 M
NaCl, and 2 mM EDTA (pH 7.4) and soni-
cated brieﬂy (Virsonic Cell Disrupter, Virtis,
Gardiner, NY). Hoechst 33258 (Sigma
Chemical Co., St. Louis, MO) was added to a
ﬁnal concentration of 1 µg/mL. Samples were
then read in a spectrofluorometer using an
excitation wavelength of 356 nm and an emis-
sion wavelength of 458 nm, and were quanti-
tated using standards of purified DNA. The
total concentration of tissue proteins was
assayed spectrophotometrically by dye binding
(Smith et al. 1985); in addition, we assessed
the concentration of membrane proteins from
the membrane preparations used for radio-
ligand binding, as described below.
ACh markers. Aliquots of the same
homogenate used for DNA determinations
were assayed in duplicate for ChAT using
established procedures (Qiao et al. 2003,
2004). Each tube contained final concentra-
tions of 60 mM sodium phosphate (pH 7.9),
200 mM NaCl, 20 mM choline chloride,
17 mM MgCl2, 1 mM EDTA, 0.2% Triton
X-100, 0.12 mM physostigmine, 0.6 mg/mL
bovine serum albumin, and 50 µM
[14C]acetyl-coenzyme A. Blanks contained
homogenization buffer instead of the tissue
homogenate. Samples were preincubated for
15 min on ice and transferred to a 37°C water
bath for 30 min; the reaction was terminated
by placing the samples on ice. Labeled acetyl-
choline was then extracted and counted, and
the activity was determined relative to tissue
protein (Smith et al. 1985). Preliminary
determinations established that enzyme activ-
ity was linear with time and tissue concentra-
tion under these conditions.
For measurements of HC3 binding, an
aliquot of the same tissue homogenate was
sedimented at 40,000 × g for 15 min and the
supernatant solution was discarded. The
membrane pellet was resuspended (Polytron)
in the original volume of buffer and resedi-
mented, and the resultant pellet was resus-
pended using a smooth glass homogenizer
fitted with a Teflon pestle, in 10 mM
sodium–potassium phosphate buffer (pH 7.4)
containing 150 mM NaCl. An aliquot was
withdrawn for the determination of mem-
brane protein (Smith et al. 1985), and radio-
ligand binding was evaluated with 2 nM
[3H]HC3 (Qiao et al. 2003, 2004), with
incubation for 20 min at room temperature,
followed by rapid vacuum ﬁltration onto glass
ﬁber ﬁlters (presoaked for 30 min with 0.15%
polyethyleneimine in buffer). The nonspeciﬁc
component was deﬁned as radioligand bind-
ing in the presence of an excess concentration
of unlabeled HC3 (10 µM), and binding val-
ues were expressed relative to membrane pro-
tein. For nAChR binding, each assay
contained a final concentration of 1 nM
[3H]cytisine in a total volume of 250 µL of a
buffer consisting of 120 mM NaCl, 5 mM
KCl, 2.5 mM CaCl2, 1 mM MgCl2, and
50 mM Tris (pH 7.4). Incubations lasted
75 min at 4°C, with or without 10 µM nico-
tine to displace speciﬁc binding.
Diazinon developmental neurotoxicity
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means and SEs. Because we evaluated multiple
neurochemical variables that were all related to
cell number and size, or to ACh synapses, the
initial comparisons were conducted by a
global analysis of variance (ANOVA; data
were log-transformed because of heteroge-
neous variance among ages, regions, and mea-
sures) incorporating all the variables and
measurements for each of the two classes so as
to avoid an increased probability of type 1
errors that might otherwise result from multi-
ple tests of the same data set: for cell develop-
ment parameters, DNA per gram of tissue,
DNA per region, total protein per DNA ratio,
membrane protein per total protein ratio; for
ACh synapses, ChAT activity, HC3 binding,
and nAChR binding. Where we identified
interactions of treatment with the other vari-
ables, data were then subdivided for lower-
order ANOVAs to evaluate treatments that
differed from the corresponding control;
where permitted by the interaction terms,
individual groups that differed from the corre-
sponding control values in a given region at a
given age were identified with Fisher’s pro-
tected least-significant difference test.
Significance was assumed at the level of
p < 0.05 for main effects; however, for interac-
tions at p < 0.1, we also examined whether
lower-order main effects were detectable after
subdivision of the interactive variables
(Snedecor and Cochran 1967). For conve-
nience, some of the results are presented as the
percent change from control values, but statis-
tical comparisons were conducted only on the
original data. The corresponding control val-
ues are shown in Tables 1 and 2, so the reader
can readily derive the original values.
Results
Neural cell development markers. Neonatal
DZN treatment did not elicit any deﬁcits in
body or brain region weights (data not
shown). Nevertheless, we found significant
effects on the markers for neural cell number
and size in adolescence and adulthood. Global
repeated-measures ANOVA incorporating all
Slotkin et al.
342 VOLUME 116 | NUMBER 3 | March 2008 • Environmental Health Perspectives
Table 2. Control values for cholinergic markers.
PND30 PND60 PND100
Measure Region Male Female Male Female Male Female
ChAT activity (pmol/min per mg protein) f/p cx 763 ± 36 728 ± 42 706 ± 26 740 ± 29 785 ± 21 833 ± 18
t/o cx 454 ± 29 458 ± 18 624 ± 17 595 ± 22 560 ± 18 592 ± 14
hp 643 ± 28 611 ± 33 689 ± 2 685 ± 9 769 ± 14 774 ± 22
st 573 ± 24 539 ± 39 864 ± 57 973 ± 37 1,318 ± 97 1,356 ± 63
mb 775 ± 13 770 ± 24 —a —a 620 ± 21 681 ± 5*
HC3 binding (fmol/mg protein) f/p cx 15.9 ± 0.7 16.7 ± 1.4 14.1 ± 0.4 14.3 ± 0.5 14.1 ± 0.6 13.6 ± 0.8
t/o cx 15.4 ± 0.8 15.5 ± 0.5 12.8 ± 0.8 12.2 ± 0.7 13.2 ± 0.4 16.5 ± 1.0*
hp 26.6 ± 2.0 26.2 ± 1.0 19.3 ± 0.4 21.9 ± 0.8* 18.3 ± 0.7 17.8 ± 0.9
st 71 ± 4 60 ± 2* 67 ± 3 74 ± 4 72 ± 2 76 ± 3
mb 15.2 ± 0.7 15.4 ± 1.1 12.4 ± 0.3 12.9 ± 0.4 12.6 ± 0.4 12.3 ± 0.6
nAChR binding (fmol/mg protein) f/p cx 66 ± 3 64 ± 2 62 ± 1 59 ± 2 53 ± 2 48 ± 2
t/o cx 87 ± 4 78 ± 1 70 ± 2 70 ± 3 63 ± 2 66 ± 2
hp 46 ± 3 45 ± 2 38 ± 2 40 ± 2 32 ± 1 29 ± 2
st 88 ± 4 72 ± 3* 72 ± 1 68 ± 3 61 ± 1 60 ± 2
mb 102 ± 3 96 ± 3 74 ± 3 71 ± 1 67 ± 2 67 ± 2
Abbreviations: f/p cx, frontal/parietal cortex; hp, hippocampus; mb, midbrain; st, striatum; t/o cx, temporal/occipital cortex. Data are means ± SEs obtained from six animals of each sex
at each age. 
aChAT is missing because of a technical error for the samples on that day. *Females signiﬁcantly different from males. 
Table 1. Control values for cell development markers.
PND30 PND60 PND100
Measure Region Male Female Male Female Male Female
DNA concentration (µg/g tissue) f/p cx 1,053 ± 24 1,088 ± 32 937 ± 26 903 ± 33 829 ± 25 868 ± 17
t/o cx 775 ± 17 844 ± 21* 749 ± 17 705 ± 22 813 ± 22 828 ± 16
hp 752 ± 12 760 ± 32 681 ± 31 680 ± 37 674 ± 25 794 ± 30*
st 816 ± 47 855 ± 76 928 ± 96 975 ± 90 864 ± 42 740 ± 36
mb 851 ± 10 898 ± 11* 759 ± 16 795 ± 14 863 ± 17 893 ± 23
bs 797 ± 15 802 ± 28 756 ± 12 786 ± 13 621 ± 9 670 ± 17*
DNA content (µg/region) f/p cx 542 ± 28 562 ± 18 608 ± 24 576 ± 42 580 ± 8 538 ± 18
t/o cx 264 ± 7 275 ± 4 267 ± 6 271 ± 7 253 ± 12 255 ± 7
hp 75 ± 4 80 ± 3 79 ± 3 81 ± 3 85 ± 4 86 ± 5
st 80 ± 2 77 ± 3 113 ± 8 109 ± 5 116 ± 4 93 ± 6*
mb 222 ± 8 223 ± 2 229 ± 8 231 ± 7 308 ± 12 299 ± 10
bs 113 ± 4 112 ± 3 149 ± 2 149 ± 7 152 ± 5 144 ± 3
Total protein/DNA (µg/µg) f/p cx 81 ± 2 80 ± 2 97 ± 2 97 ± 2 92 ± 3 93 ± 3
t/o cx 88 ± 1 86 ± 1 106 ± 7 119 ± 6 102 ± 3 98 ± 3
hp 83 ± 2 78 ± 2 110 ± 3 113 ± 6 117 ± 4 113 ± 2
st 87 ± 3 102 ± 3* 89 ± 4 86 ± 4 85 ± 3 94 ± 4
mb 89 ± 2 92 ± 1 109 ± 3 104 ± 3 97 ± 4 95 ± 2
bs 96 ± 2 97 ± 3 110 ± 2 106 ± 2 136 ± 3 134 ± 2
Membrane protein/total protein (%) f/p cx 38 ± 1 37 ± 1 53 ± 1 54 ± 1 53 ± 1 54 ± 1
t/o cx 45 ± 2 44 ± 1 39 ± 1 39 ± 2 46 ± 1 46 ± 2
hp 49 ± 1 49 ± 1 54 ± 2 55 ± 1 50 ± 2 46 ± 2
st 48 ± 1 48 ± 3 46 ± 3 46 ± 2 57 ± 2 59 ± 2
mb 50 ± 1 48 ± 1 46 ± 1 48 ± 1 56 ± 2 55 ± 1
bs 48 ± 2 47 ± 1 46 ± 2 47 ± 1 46 ± 1 44 ± 2
Abbreviations: bs, brain stem; f/p cx, frontal/parietal cortex; hp, hippocampus; mb, midbrain; st, striatum; t/o cx, temporal/occipital cortex. Data are means ± SEs obtained from six ani-
mals of each sex at each age.
*Females signiﬁcantly different from males. Diazinon developmental neurotoxicity
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the cell-development variables (treatment, age,
region, sex, four measures) indicated a main
treatment effect for DZN (p < 0.03), reﬂect-
ing a signiﬁcant overall difference for the low-
dose DZN group compared with either
controls (p < 0.03) or the high-dose DZN
group (p < 0.003). In addition, the treatment
effect showed interactions with region, age,
and measure: p < 0.02 for treatment × region;
p < 0.08 for treatment × age; p < 0.02 for
treatment × measure; and p < 0.05 for treat-
ment × region × measure. Accordingly, data
were subdivided into individual measures
(DNA concentration, DNA content, total
protein/DNA, membrane protein/total protein)
and reexamined for treatment effects and
interactions with the remaining variables.
Because there were no interactions of treat-
ment × sex or treatment × sex × other vari-
ables, treatment effects are shown combined
for males and females; however, the sex factor
was retained in performing the lower-order
statistical analyses.
For DNA concentration, we observed a
small but highly statistically signiﬁcant overall
increase at the lower DZN dose (Figure 1A).
The effect was less notable at the higher dose,
which did not show statistically significant
differences from the control group; in fact,
the increase seen at the low dose was itself
distinguishable from the lack of effect in the
high-dose group (p < 0.04). Although increases
were also seen for DNA content, the marker
for total neural cell numbers, there were signiﬁ-
cant regional distinctions (Figure 1B). Values
were increased with either 0.5-mg/kg or
2-mg/kg DZN in the frontal/parietal cortex
and the brainstem, whereas there were
decreases at either dose in the temporal/
occipital cortex and at the higher dose in the
striatum.
The effects on protein-related markers
were far less notable at the low dose of DZN,
as neither the total protein/DNA ratio
(Figure 2A) nor the membrane protein/total
Figure 1. Effects of neonatal DZN exposure on indices of cell-packing density and total cell number. (A) DNA concentration (DNA per unit tissue weight). (B) DNA
content (DNA per brain region). Abbreviations: bs, brain stem; f/p cx, frontal/parietal cortex; hp, hippocampus; mb, midbrain; st, striatum; t/o cx, temporal/occipital
cortex. Data represent means ± SEs obtained from six animals of each sex in each treatment group at each age, presented as the percentage change from con-
trol values shown in Table 1. Values for males and females were combined because of the absence of interactions of treatment × sex or treatment × sex × other
variables. Multivariate ANOVA for all factors (all treatments, both sexes, all ages, all regions) were performed. In (A), there was an overall main treatment effect
(p < 0.02), with signiﬁcant differences from the control restricted to the DZN 0.5 group (p < 0.009). Further subdivisions of the data were not examined because of
the absence of interactions of treatment with the other variables. In (B), treatment × region is signiﬁcant at p < 0.004, and lower-order ANOVAs for each region
appear within the panel; subdivision into separate ages was not carried out because of the absence of an interaction of treatment × age. 
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Figure 2. Effects of neonatal DZN exposure on indices of cell size. (A) Total protein/DNA ratio. (B) Membrane protein/total protein ratio. Abbreviations: bs, brain
stem; f/p cx, frontal/parietal cortex; hp, hippocampus; mb, midbrain; st, striatum; t/o cx, temporal/occipital cortex. Data represent means ± SEs obtained from six
animals of each sex in each treatment group at each age, presented as the percentage change from control values shown in Table 1. Values for males and
females were combined because of the absence of interactions of treatment × sex or treatment × sex × other variables. Multivariate ANOVA for all factors (all
treatments, both sexes, all ages, all regions) were performed. In (A), there was an overall main treatment effect (p < 0.05), as well as an interaction of treatment ×
region (p < 0.07). The main effect was signiﬁcant for the DZN 2 group (p < 0.05) and lower-order ANOVAs for each region identiﬁed a signiﬁcant difference only in
the striatum (p < 0.03). Subdivision into separate ages was not carried out because of the absence of an interaction of treatment × age. In (B), there was an over-
all main treatment effect (p < 0.05), with signiﬁcant differences from the control restricted to the DZN 2 group (p < 0.03). Further subdivisions of the data were not
examined because of the absence of interactions of treatment with the other variables. 
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PNDprotein ratio (Figure 2B) showed significant
differences. Raising the DZN dose to 2 mg/kg
revealed a significant (p < 0.05) overall
increase in the total protein/DNA ratio that
was particularly prominent in the striatum
(Figure 2A); there was also a significant
(p < 0.03) overall decrement in the membrane
protein/total protein ratio (Figure 2B).
ACh markers. Global ANOVA for the
ACh markers (treatment, age, region, sex, three
measures) identiﬁed interactions of DZN treat-
ment with the other variables, in this case,
necessitating separation of effects on males and
females: p < 0.04 for treatment × age × sex;
p < 0.07 for treatment × age × region; p < 0.03
for treatment × region × measure; p < 0.002
for treatment × age × region × measure;
p < 0.02 for treatment × sex × region × mea-
sure; and p < 0.08 for treatment × age × sex ×
region × measure. Thus, for these variables, we
performed lower-order analyses on each meas-
ure separately for each region and sex.
In the frontal/parietal cortex, we found
substantial decreases in ChAT in adolescence
(PND30) in males exposed to DZN but no
apparent changes in HC3 binding, the index
of presynaptic neural activity (Figure 3). At
PND100, the only significant effect was a
decrease in nAChR binding, again restricted
to males. More robust effects were seen in the
temporal/occipital cortex (Figure 4). In males,
there were deficits in adolescence or early
adulthood for ChAT (PND60), HC3 binding
(PND30), and nAChR binding (PND30),
again displaying more preponderant effects at
the low-DZN dose rather than the high dose.
In females, there were robust decreases in
ChAT and nAChR binding at PND30 and a
large deficit in HC3 binding at PND100.
Effects on the hippocampus differed from
those in the cerebrocortical regions in that
there was little or no effect apparent early on
(PND30), but deﬁcits emerged in adulthood
(Figure 5). Males showed deficiencies in
ChAT on PND100 and females showed a
reduction in HC3 binding at PND60.
The striatum showed unique and robust
effects of DZN (Figure 6). On PND30, we
observed marked increases in ChAT activity in
both males and females; although the effect
persisted in males through PND60, both sexes
showed regression by PND100. At that point,
ChAT was reduced in females at the high-
DZN dose, an effect that was paralleled by a
decrease in HC3 binding. Males displayed a
transient increase in hippocampal HC3 bind-
ing (PND60) that was no longer evident by
PND100. For nAChR binding, the only effect
was an increase at PND30 in females exposed
to the high-DZN dose. We observed no signiﬁ-
cant effects on ACh markers in the midbrain,
the location of many of the ACh cell bodies
that project to the other regions (Figure 7).
Discussion
Behavioral evaluations of adolescent and adult
rats exposed as neonates to DZN doses below
or just above the threshold for detectable
cholinesterase inhibition indicate lasting
deficits in cognitive performance and alter-
ations in emotional responsiveness (Roegge
et al. 2008; Timofeeva et al. 2008). Results of
the present study show that these changes are
associated with corresponding effects on
indices of neural cell development and ACh
synaptic function. For the cell development
markers, the low dose of DZN, which does
not cause any discernible cholinesterase inhibi-
tion (Slotkin et al. 2006b), evoked a small but
consistent increase in the DNA concentration
in various brain regions, indicative of an
increase in cell-packing density (i.e., more cells
per unit volume). Typically, this reﬂects a loss
of neurons and their replacement by smaller
Slotkin et al.
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Figure 3. Effects of neonatal DZN exposure on cholinergic markers in the frontal/parietal cortex. Data repre-
sent means ± SEs obtained from six animals of each sex in each treatment group at each age, presented as
the percentage change from control values shown in Table 2. Multivariate ANOVA for all factors (all treat-
ments, both sexes, all ages, all measures): p < 0.02 for treatment × age × sex × measure. Because treatment
interacted with all the other variables, separate tests were conducted for each treatment and measure at
each age, separated by sex. 
*Signiﬁcantly different from control values.
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Figure 4. Effects of neonatal DZN exposure on cholinergic markers in the temporal/occipital cortex. Data
represent means ± SEs obtained from six animals of each sex in each treatment group at each age, pre-
sented as the percentage change from control values shown in Table 2. Multivariate ANOVA for all factors
(all treatments, both sexes, all ages, all measures): p < 0.04 for treatment × sex × measure, and p < 0.03 for
treatment × age × sex × measure. Because treatment interacted with all the other variables, separate tests
were conducted for each treatment and measure at each age, separated by sex. 
*Signiﬁcantly different from control values.
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PNDglial cells (O’Callaghan 1988); in keeping with
this interpretation, the total number of cells
(DNA content) showed a signiﬁcant increase
in two of the regions (frontal/parietal cortex,
brainstem), as would be expected from reac-
tive gliosis. In contrast, one region (tempo-
ral/occipital cortex) showed a decrease in
DNA content, indicative of even greater net
toxicity that compromises the total number of
cells. In turn, this suggests a biphasic response,
with neuronal loss and glial “scarring” in the
less sensitive regions, and loss of both neurons
and glia in the more sensitive regions. Indeed,
DZN is inherently more toxic toward glial
cells than neurons (Qiao et al. 2001); how-
ever, glia, unlike neurons, can be replaced, so
the net effect reflects the balance between
damage and repair, which are likely to vary
among brain regions simply because they dif-
fer in their maturational state at the time of
exposure (Rodier 1988). This conclusion is
strongly supported by the finding that
increasing the dose of DZN to 2 mg/kg
reduced the effect on cell-packing density to
nonsigniﬁcance and enhanced the net cell loss
as exemplified by DNA content, extending
the deficits to include the striatum. The
biphasic effect is thus suggestive of incremen-
tally greater gliotoxicity at the higher dose, in
agreement with prior measurements of the
expression of gliotypic genes in the immediate
postexposure period (Slotkin and Seidler
2007a). Obviously, though, quantitative mor-
phologic examinations will be required to
provide complete proof of these conclusions,
as has been done for chlorpyrifos (Slotkin
1999, 2004, 2005): Homogenization of brain
regions containing diverse neuronal groupings
means that even drastic effects on a specific
population of neurons may go unnoticed
because of dilution with unaffected areas
(Qiao et al. 2002, 2003). Despite this limita-
tion, we found statistically significant altera-
tions in biomarkers of cell number and
cell-packing density, indicating that much
larger changes are likely to be present in more
restricted neuroanatomical locations.
In contrast to the effects on indices of cell-
packing density and cell number, the markers
related to cell growth and size were less notably
affected by DZN exposure and were limited to
effects at the higher dose. There was a small
but significant overall increase in total pro-
tein/DNA, achieving statistical signiﬁcance in
one region (striatum), as well as a small overall
decrease in membrane/total protein. The main
point is that DZN exposure targets cell num-
bers more than it targets cell growth.
Nevertheless, the protein measures reinforce
some of the conclusions from the DNA meas-
urements; the increase in total protein/DNA in
the striatum is the opposite of what would be
expected from an elevation in the number of
glial cells, because the smaller glia would have
lower protein per cell. Similarly, the small
decrease in membrane/total protein is sugges-
tive of a negative impact on generation of neu-
ritic projections, effects that have already been
clearly demonstrated for DZN in vitro
(Axelrad et al. 2002, 2003). Furthermore, in
earlier work, we found that neonatal DZN
exposure in vivo immediately shifts the expres-
sion of genes required for the generation
of neurites (Slotkin and Seidler 2007a) and
produces a drop in membrane/total protein
prior to the stage at which glia are being gener-
ated (Slotkin et al. 2006a). It is thus highly
likely that DZN, like chlorpyrifos (Axelrad
et al. 2003; Das and Barone 1999; Howard
et al. 2005), compromises the development of
neuronal projections. Accordingly, there is no
reason to suspect that adverse effects will be
limited to the ACh systems studied here, even
though, as described below, there is profound
Diazinon developmental neurotoxicity
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Figure 5. Effects of neonatal DZN exposure on cholinergic markers in the hippocampus. Data represent
means ± SEs obtained from six animals of each sex in each treatment group at each age, presented as the
percentage change from control values shown in Table 2. Multivariate ANOVA for all factors (all treat-
ments, both sexes, all ages, all measures): p < 0.03 for treatment × age × sex, and p < 0.07 for treatment ×
age × sex × measure. Because treatment interacted with all the other variables, separate tests were con-
ducted for each treatment and measure at each age, separated by sex. 
*Signiﬁcantly different from control values.
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Figure 6. Effects of neonatal DZN exposure on cholinergic markers in the striatum. Data represent
means ± SEs obtained from six animals of each sex in each treatment group at each age, presented as the
percentage change from control values shown in Table 2. Multivariate ANOVA for all factors (all treat-
ments, both sexes, all ages, all measures): p < 0.003 for treatment × age, p < 0.02 for treatment × measure,
and p < 0.004 for treatment × age × measure. Because treatment interacted with all the other variables,
separate tests were conducted for each treatment and measure at each age, separated by sex. 
*Signiﬁcantly different from control values. 
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PNDdisruption of ACh functional indices. Indeed,
we have already shown that there are both
immediate and lasting deﬁcits in serotonergic
synaptic function after apparently subtoxic
neonatal DZN exposures (Slotkin et al. 2006b,
in press; Slotkin and Seidler 2007a).
In the two cerebrocortical regions and the
hippocampus, DZN elicited profound deﬁcits
in all three ACh synaptic markers in either
adolescence or adulthood, with differing pro-
files according to region. These findings all
point toward deﬁciencies in ACh innervation,
ACh synaptic activity, or ACh receptor expres-
sion, producing a net outcome of impairment
of ACh synaptic function. In the frontal/pari-
etal cortex, the deficits were seen in males,
whereas both sexes showed adverse effects in
the temporal/occipital cortex. In the hip-
pocampus, the deﬁcits emerged in adulthood
after apparent normality in adolescence; this
reinforces the idea that developmental neuro-
toxicant exposures can act in two distinct ways,
producing immediate damage or changing the
trajectory of neurodevelopment so that alter-
ations appear after a substantial delay. The hip-
pocampal and cortical ACh impairments are
particularly important in light of the cognitive
and emotional dysfunction seen with this
DZN exposure model (Roegge et al. 2008;
Timofeeva et al. 2008). The nonmonotonic
dose–effect relationship for effect on ACh sys-
tems precisely mirrors that seen for cognitive
impairment (Timofeeva et al. 2008). In that
study, we found that the animals given the low
dose of DZN were sensitized to the amnestic
effects of scopolamine, a muscarinic ACh
antagonist, results entirely in keeping with
compromised ACh function as seen here.
In contrast to the other regions containing
major ACh projections, the striatum showed
an entirely different pattern of effects, with ini-
tial increases in the ACh markers, followed by
a regression to normal or subnormal values at
later stages. The striatum differs in several sub-
stantial ways; for example, striatal ACh neu-
rons are short-axon interstitial cells rather than
the long-projection neurons found in the other
regions. Furthermore, its high concentration of
dopaminergic projections conveys a conse-
quently greater susceptibility to oxidative stress,
including that elicited by pesticide exposures
(Hirsch 1994; Junn and Mouradian 2001;
Karen et al. 2001; Kitazawa et al. 2001;
Olanow and Arendash 1994). In comparative
studies of gene expression patterns and markers
of the cell damage/repair response, we found
that DZN has a greater propensity to elicit
these types of effects than does chlorpyrifos
(Jameson et al. 2007; Slotkin and Seidler
2007a), so the striatum may represent a more
specific regional target for DZN. Further,
neonatal DZN exposure interferes with the
expression of speciﬁc neurotrophic factors that
govern the development of striatal dopamine
systems (Slotkin et al. 2007c). Our results
therefore suggest that DZN evokes a signifi-
cant loss of dopaminergic projections and/or
dopaminergic function, and a consequent inva-
sion of dopaminergic terminal zones with
ACh. Indeed, we have seen just this type of
neurotransmitter replacement for the loss of
hippocampal ACh function after developmen-
tal exposure to chlorpyrifos, where serotonergic
projections instead take over the innervation
and function of nominally cholinergic terminal
zones (Aldridge et al. 2005a, 2005b; Icenogle
et al. 2004; Levin et al. 2001, 2002). It would
clearly be worthwhile to expand the scope of
investigation to include dopamine systems;
developmental loss of dopamine projections as
a result of environmental toxicant exposure are
suspected to underlie the later emergence of
Parkinson disease (Cory-Slechta et al. 2005;
Kamel and Hoppin 2004; Landrigan et al.
2005), and our ﬁndings of a rapid decline in
striatal ACh markers in adulthood points to a
progressive loss of other aspects of synaptic
function in this region.
Because we observed adverse effects of
DZN at exposures below the threshold for any
detectable cholinesterase inhibition, it is likely
that the underlying cellular mechanisms
involve other actions on specific processes
involved in neural cell replication and differen-
tiation (Barone et al. 2000; Betancourt et al.
2006; Betancourt and Carr 2004; Casida and
Quistad 2004; Gupta 2004; Pope 1999; Qiao
et al. 2002, 2003; Slotkin 1999, 2004, 2005;
Slotkin et al. 2007c; Yanai et al. 2002). If this
is true, then there is no reason to expect that
the effects of DZN will be the same as those of
other organophosphates, such as chlorpyrifos,
even when selected doses are dynamically
equivalent, that is, that occupy the same part of
the dose–response curve just below and at the
threshold for cholinesterase inhibition. Indeed,
our results indicate just that. Whereas DZN
increased the cell-packing density, chlorpyrifos
does the opposite (Qiao et al. 2003), represent-
ing its greater propensity for gliotoxicity
(Garcia et al. 2001; Qiao et al. 2001).
Although both DZN and chlorpyrifos (Qiao
et al. 2003; Slotkin et al. 2001) reduce ChAT
activity in cerebrocortical areas and hippocam-
pus in adolescence and adulthood, they differ
in their regional targeting and sex selectivity.
Strikingly, whereas we found that DZN ele-
vated many of the striatal ACh markers in
either adolescence or young adulthood, chlor-
pyrifos has the opposite effect (Qiao et al.
2003; Slotkin et al. 2001). As one point of
convergence, both DZN and chlorpyrifos
largely spare the midbrain, which contains
higher concentrations of ACh cell bodies as
distinct from terminals. Nevertheless, given the
large disparities in their effects in the brain
regions containing the major ACh projections,
these results do provide a mechanistic under-
pinning for the notable differences in behav-
ioral outcomes after otherwise equivalent
neonatal exposures to these two organophos-
phates (Aldridge et al. 2005a; Levin et al.
2001, 2002; Roegge et al. 2008; Timofeeva
et al. 2008).
In conclusion, early postnatal exposure to
DZN, at doses insufficient to cause any dis-
cernible signs of exposure and below the
threshold for inhibition of cholinesterase,
nevertheless elicits lasting changes in indices
of neural cell development and ACh synaptic
Slotkin et al.
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Figure 7. Effects of neonatal DZN exposure on cholinergic markers in the midbrain. Data represent
means ± SEs obtained from six animals of each sex in each treatment group at each age, presented as the
percentage change from control values shown in Table 2. Multivariate ANOVAs for all factors (all treat-
ments, both sexes, all ages) were conducted separately for each of the measures because of the missing
values for ChAT on PND60; none of these were signiﬁcant. Accordingly, no lower-order tests on subdivi-
sions of the data were carried out. 
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PNDfunction. Together with our recent behavioral
studies showing impairment of cognitive
function and altered emotional responses
(Roegge et al. 2008; Timofeeva et al. 2008),
these results point to the inadequacy of
cholinesterase measurements alone as a bio-
marker for defining the safe exposure limits
for developmental neurotoxicity of organo-
phosphates. Further, the nonmonotonic
dose–effect relationships seen for both DZN
and chlorpyrifos in terms of ACh systems and
corresponding behavioral outcomes highlight
the importance of examining dose ranges well
below those required for cholinesterase inhibi-
tion. Given the variety of mechanisms of
action of these compounds, toxic effects may
be unmasked at lower doses where potentially
counteracting secondary effects are no longer
taking place. Finally, the dichotomous out-
comes of exposure to DZN compared with
chlorpyrifos reinforce the conclusion that
although organophosphates, as a class, target
neural cell development and ACh systems,
each organophosphate is likely to elicit a
unique pattern of damage/repair and altered
synaptic function.
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